@article {LuPA3647, author = {Fang-Ying Lu and Rong Chen and Kandi Xu and Jie Huang and Dexiang Yang and Tao Bai and Yun Feng and Yi Guo}, title = {Liver dysfunction on admission worsen clinical manifestations and outcomes of Coronavirus Disease 2019}, volume = {58}, number = {suppl 65}, elocation-id = {PA3647}, year = {2021}, doi = {10.1183/13993003.congress-2021.PA3647}, publisher = {European Respiratory Society}, abstract = {Background: Liver dysfunction was a common manifestation in Coronavirus Disease 2019 (COVID-19), but its association with clinical features and poor prognosis hasn{\textquoteright}t been fully delineated.Methods: Laboratory confirmed COVID-19 patients were enrolled and classified into normal live function group and liver dysfunction group according to liver enzymes, bilirubin and albumin in admission, respectively. Baseline, clinical features and outcomes~were collected and compared in the paired groups.Results: Of the 649 included COVID-19 patients, 200(30.82\%), 69(10.63\%), 267(41.14\%) patients had elevated liver enzymes, increased bilirubin and low-level albumin, respectively. Fever, cough and dyspnea were the most common symptoms and showed increased proportion in liver dysfunction group. Compared with patients in normal liver function group, patients with liver dysfunction manifested decreased lymphocytes, higher level of leukocytes, neutrophils, inflammatory indicators and cytokines, as well as more severe impairment in kidney function and myocardium. They were more likely to show bilateral involvement and more pulmonary lobes involved according to chest images. With increased proportion of patients who developed severe/critical, needed mechanical ventilation and systemic glucocorticoid therapy, liver dysfunction on admission showed significantly higher in-hospital mortality. Moreover, cardiac troponin I >=1.5ng/mL was identified as independent mortality predictor in elevated liver enzymes group.Conclusion: Patients with liver dysfunction on admission had worse clinical manifestation, and resulted in higher rate of severe/critical type, receiving mechanical ventilation and in-hospital mortality.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3647.This abstract was presented at the 2021 ERS International Congress, in session {\textquotedblleft}Prediction of exacerbations in patients with COPD{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/58/suppl_65/PA3647}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }